Brokerages Anticipate Tekmira Pharmaceuticals to Post ($0.31) Earnings Per Share (NASDAQ:TKMR)

Tekmira Pharmaceuticals (NASDAQ:TKMR) has received an average broker rating score of 1.50 (Buy) from the six brokers that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a hold rating, one has issued a buy rating and four have given a strong buy rating to the company. Tekmira Pharmaceuticals’ rating score has declined by 18% in the last 90 days as a result of various analysts’ upgrades and downgrades.

Brokerages have set a twelve-month consensus target price of $27.00 for the company and are forecasting that the company will post ($0.31) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Tekmira Pharmaceuticals an industry rank of 47 out of 265 based on the ratings given to related companies.

TKMR has been the subject of a number of recent research reports. Analysts at Maxim Group cut their price target on shares of Tekmira Pharmaceuticals from $31.00 to $21.00 in a research note on Monday, December 22nd. They now have a “buy” rating on the stock. Separately, analysts at initiated coverage on shares of Tekmira Pharmaceuticals in a research note on Monday, November 10th. They set a “sell” rating on the stock. Finally, analysts at Stifel Nicolaus reiterated a “buy” rating on shares of Tekmira Pharmaceuticals in a research note on Friday, November 7th. They now have a $26.00 price target on the stock, down previously from $31.00.

Tekmira Pharmaceuticals (NASDAQ:TKMR) opened at 15.15 on Friday. Tekmira Pharmaceuticals has a 1-year low of $7.65 and a 1-year high of $31.48. The stock has a 50-day moving average of $14.63 and a 200-day moving average of $16.53.

Tekmira Pharmaceuticals (NASDAQ:TKMR) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by $0.08. The company had revenue of $4.40 million for the quarter, compared to the consensus estimate of $3.71 million. The company’s revenue for the quarter was up 46.7% on a year-over-year basis. On average, analysts predict that Tekmira Pharmaceuticals will post $-1.61 earnings per share for the current fiscal year.

Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing ribonucleic acid (NASDAQ:TKMR) interference (RNAi) therapeutics and providing its lipid nanoparticle (LNP) delivery technology to pharmaceutical and biotechnology partners.

To get a free copy of the research report on Tekmira Pharmaceuticals (TKMR), click here. For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Tekmira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tekmira Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.

Latest News

Instacart the Grocery Delivery Startup Raises $210 Million
Instacart the Grocery Delivery Startup Raises $210 Million
China Will Relax Regulations on Banks Renminbi Trading
China Will Relax Regulations on Banks Renminbi Trading
Subway in Safety Scandal in China over Food
Subway in Safety Scandal in China over Food
UPS and FedEx Make Improvements During Holiday Season
UPS and FedEx Make Improvements During Holiday Season
MasterCard Spending Report for Holidays Shows Weak Electronics
MasterCard Spending Report for Holidays Shows Weak Electronics
Gift Cards Have Become Hugely Popular, but Have Risks
Gift Cards Have Become Hugely Popular, but Have Risks


Leave a Reply

Advertisement
Advertisement
© 2006-2015 Leoncheng.